These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 27629160)

  • 1. Aripiprazole augmentation in highly treatment-resistant obsessive-compulsive disorder - experience from a specialty clinic in India.
    Hegde A; Kalyani BG; Arumugham SS; Narayanaswamy JC; Math SB; Reddy YC
    Int J Psychiatry Clin Pract; 2017 Mar; 21(1):67-69. PubMed ID: 27629160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of Risperidone Augmentation in Obsessive-Compulsive Disorder: Experience From a Specialty Clinic in India.
    Hegde A; Kalyani BG; Arumugham SS; Narayanaswamy JC; Math SB; Reddy YC
    J Clin Psychopharmacol; 2016 Aug; 36(4):381-4. PubMed ID: 27219093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 10-week open-label study.
    Ak M; Bulut SD; Bozkurt A; Ozsahin A
    Adv Ther; 2011 Apr; 28(4):341-8. PubMed ID: 21437763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials.
    Dold M; Aigner M; Lanzenberger R; Kasper S
    Int J Neuropsychopharmacol; 2015 May; 18(9):. PubMed ID: 25939614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vortioxetine and Aripiprazole Combination in Treatment-Resistant Obsessive-Compulsive Disorder: A Case Report.
    De Berardis D; Olivieri L; Nappi F; Rapini G; Vellante F; Matarazzo I; Serroni N; Di Giannantonio M
    J Clin Psychopharmacol; 2017 Dec; 37(6):732-734. PubMed ID: 29040153
    [No Abstract]   [Full Text] [Related]  

  • 6. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 12-week open-label preliminary study.
    Pessina E; Albert U; Bogetto F; Maina G
    Int Clin Psychopharmacol; 2009 Sep; 24(5):265-9. PubMed ID: 19629012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antipsychotic augmentation for treatment resistant obsessive-compulsive disorder: what if antipsychotic is discontinued?
    Maina G; Albert U; Ziero S; Bogetto F
    Int Clin Psychopharmacol; 2003 Jan; 18(1):23-8. PubMed ID: 12490771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials.
    Dold M; Aigner M; Lanzenberger R; Kasper S
    Int J Neuropsychopharmacol; 2013 Apr; 16(3):557-74. PubMed ID: 22932229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a single-blind, randomised study.
    Selvi Y; Atli A; Aydin A; Besiroglu L; Ozdemir P; Ozdemir O
    Hum Psychopharmacol; 2011 Jan; 26(1):51-7. PubMed ID: 21308781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
    Bloch MH; Landeros-Weisenberger A; Kelmendi B; Coric V; Bracken MB; Leckman JF
    Mol Psychiatry; 2006 Jul; 11(7):622-32. PubMed ID: 16585942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of Venlafaxine in Selective Serotonin Reuptake Inhibitor-Resistant Obsessive-Compulsive Disorder: Experience From a Specialty Clinic in India.
    Balachander S; Kodancha PG; Arumugham SS; Sekharan JT; Narayanaswamy JC; Reddy YCJ
    J Clin Psychopharmacol; 2019; 39(1):82-85. PubMed ID: 30516575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy and tolerability of antipsychotics as augmentations in adults with treatment-resistant obsessive-compulsive disorder: A network meta-analysis.
    Zhou DD; Zhou XX; Lv Z; Chen XR; Wang W; Wang GM; Liu C; Li DQ; Kuang L
    J Psychiatr Res; 2019 Apr; 111():51-58. PubMed ID: 30677645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder.
    Storch EA; Goddard AW; Grant JE; De Nadai AS; Goodman WK; Mutch PJ; Medlock C; Odlaug B; McDougle CJ; Murphy TK
    J Clin Psychiatry; 2013 Jun; 74(6):e527-32. PubMed ID: 23842022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study.
    Muscatello MR; Bruno A; Pandolfo G; Micò U; Scimeca G; Romeo VM; Santoro V; Settineri S; Spina E; Zoccali RA
    J Clin Psychopharmacol; 2011 Apr; 31(2):174-9. PubMed ID: 21346614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder.
    Matsunaga H; Nagata T; Hayashida K; Ohya K; Kiriike N; Stein DJ
    J Clin Psychiatry; 2009 Jun; 70(6):863-8. PubMed ID: 19422759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative, single-blind, randomized study on quetiapine and aripiperazole augmentation in treatment of selective serotonin reuptake inhibitor refractory obsessive-compulsive disorder.
    Talaei A; Hosseini FF; Aghili Z; Akhondzadeh S; Asadpour E; Mehramiz NJ; Forouzanfar F
    Can J Physiol Pharmacol; 2020 Apr; 98(4):236-242. PubMed ID: 32228235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Systematic Review of Evidence-based Treatment Strategies for Obsessive- compulsive Disorder Resistant to first-line Pharmacotherapy.
    Albert U; Marazziti D; Di Salvo G; Solia F; Rosso G; Maina G
    Curr Med Chem; 2018; 25(41):5647-5661. PubMed ID: 29278206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the Efficacy and Safety of Aripiprazole Versus Bupropion Augmentation in Patients With Major Depressive Disorder Unresponsive to Selective Serotonin Reuptake Inhibitors: A Randomized, Prospective, Open-Label Study.
    Cheon EJ; Lee KH; Park YW; Lee JH; Koo BH; Lee SJ; Sung HM
    J Clin Psychopharmacol; 2017 Apr; 37(2):193-199. PubMed ID: 28129308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Recommendations for Augmentation Agents in Obsessive-Compulsive Disorder Partially Responsive to Serotonin Reuptake Inhibitors.
    Gautam M
    J Clin Psychopharmacol; 2023 Jul-Aug 01; 43(4):369-377. PubMed ID: 37335203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aripiprazole Augmentation to Mood Stabilizers for Obsessive-Compulsive Symptoms in Bipolar Disorder.
    Di Salvo G; Maina G; Pessina E; Teobaldi E; Barbaro F; Martini A; Albert U; Rosso G
    Medicina (Kaunas); 2020 Dec; 57(1):. PubMed ID: 33374357
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.